I did notice that ONTY closed at $4.50 yesterday and closed today at $2.19. Thanks for your support. As an aside, I first invested in Biomira 6 or 7 years ago, but sold out. At the time it was a small Canadian biotech in Edmonton. At the end of 2007 Biomira changed its name to Oncothyreon, did a 1 for 6 reverse split, and moved to Seattle.
" The fact that several potential competitors are failing in their NSCLC trials IMO increases the mathematical probability that PPHM will ultimately find a suitable partner for their drug in this indication (or platform in general)."
I agree RRdog..... and partner by this spring/summer would be good!
with respect to onty value, it was already partnered with single to mid teen royalties based on approval. in march, the market cap was $500 mil plus before the trial was delayed which caused a huge selloff.